Shares of Quanterix Corp (NASDAQ:QTRX) have been given a consensus recommendation of “Buy” by the six brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $26.50.
Several research firms have weighed in on QTRX. Zacks Investment Research lowered Quanterix from a “hold” rating to a “sell” rating in a report on Wednesday, August 22nd. ValuEngine upgraded Quanterix from a “hold” rating to a “buy” rating in a report on Monday, June 11th.
NASDAQ QTRX opened at $16.43 on Monday. Quanterix has a fifty-two week low of $13.00 and a fifty-two week high of $24.81. The stock has a market cap of $348.07 million and a price-to-earnings ratio of -1.98.
Quanterix (NASDAQ:QTRX) last posted its earnings results on Friday, August 10th. The company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.06). The business had revenue of $8.64 million during the quarter, compared to the consensus estimate of $7.92 million. equities research analysts anticipate that Quanterix will post -1.2 EPS for the current year.
In other news, Chairman E Kevin Hrusovsky sold 17,909 shares of Quanterix stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $14.53, for a total value of $260,217.77. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 31.60% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of QTRX. Schwab Charles Investment Management Inc. bought a new position in shares of Quanterix in the first quarter worth about $374,000. Northern Trust Corp bought a new position in shares of Quanterix in the first quarter worth about $894,000. BlackRock Inc. bought a new position in shares of Quanterix in the first quarter worth about $3,439,000. Citadel Advisors LLC bought a new position in shares of Quanterix in the first quarter worth about $431,000. Finally, Opaleye Management Inc. increased its stake in shares of Quanterix by 130.8% in the first quarter. Opaleye Management Inc. now owns 150,000 shares of the company’s stock worth $2,556,000 after purchasing an additional 85,000 shares during the period. Institutional investors and hedge funds own 49.14% of the company’s stock.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.
Featured Article: Google Finance
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.